2021 Fiscal Year Final Research Report
Identification of allo-specific antibody responsible for the pathogenesis of neonatal hemochromatosis
Project/Area Number |
19K08339
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 52050:Embryonic medicine and pediatrics-related
|
Research Institution | Kanazawa University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
東馬 智子 金沢大学, 附属病院, 助教 (00377392)
|
Project Period (FY) |
2019-04-01 – 2022-03-31
|
Keywords | 新生児ヘモクロマトーシス / アロ抗原 / 胎児肝 / 妊娠 |
Outline of Final Research Achievements |
Neonatal hemochromatosis is a fatal disease of fetus and infants with severe liver injury and systemic iron deposition. There is indirect evidence that maternally-derived antibody against fetal organ is responsible for the disease, although the exact antigen has not been determined to date. In this study, protein-active array method was utilized to find candidate antigens of NH. Several proteins have been found as a possible target for the NH allo-reactive antibody. These targets are among proteins expressed specifically within fetal liver tissue. Further study is undergoing to prove the specificity of this antigen and to clarify the direct relationship between NH pathology and antibody directed against these antigens.
|
Free Research Field |
小児科学
|
Academic Significance and Societal Importance of the Research Achievements |
本研究では、新生児ヘモクロマトーシスの発症の分子機序を明らかにすることを目的とする。とりわけ、胎児期に母体から移行する抗原特異的IgG抗体を介して発症するとされる、臓器傷害の惹起に関わるアロ抗原を同定すること目指す。これにより、ハイリスク妊婦のスクリーニング、胎児期早期の確定診断、適切な治療介入のための新たなバイオマーカーの提案などが可能となる。 現在、高い治療効果を示すとされ、医師主導治験が行われている母体への高用量免疫グロブリン投与についても、理論的な裏付けがなされ、治療の一般化が促進されることが期待される。
|